MKMahesh Koulagi

Mahesh Koulagi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahesh Koulagi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Feasibility and safety of accelerated MVAC (aMVAC) in geriatric patients with muscle-invasive bladder cancer

    by Sai Prasath, Deepak Sundriyal, S P Harsha, Anusha Mruthyunjaya Swamy, Karthik Jayalingappa, Mayank Kapoor, Mahesh Koulagi, Vikas Kumar Panwar, Ankur Mittal, Amit Sehrawat

    Dose-dense MVAC (ddMVAC) is a standard regimen for muscle-invasive bladder cancer (MIBC), but tolerability concerns often limit its use in geriatric patients. Accelerated MVAC (aMVAC), delivered as a single-day regimen, may reduce hospital visits and resource use. This study assessed the feasibility and safety of aMVAC in geriatric patients with MIBC in a real-world, resource-constrained setting. We included patients aged 60 years or older with histologically confirmed MIBC (stages II–IV). Eligible patients received three or four cycles of single-day aMVAC (methotrexate 30 mg/m², vinblastine 3 mg/m², doxorubicin 30 mg/m², cisplatin 70 mg/m²) every 14 days, with growth factor support. Feasibility was defined as completing 3 or 4 cycles within the protocol-defined duration. Toxicities were graded per CTCAE v5.0. Among 33 geriatric patients, 30 (90.9%) completed ≥ 3 cycles, and 28 (84.8%) completed four cycles within the planned timeframe. Dose reductions for grade 3 or higher toxicities were required in 10 (30.3%) patients, and treatment discontinuation occurred in 3 (9%). Grade 3 hematologic events occurred in 12% and non-hematologic events in 33.3%; the most common were anemia, mucositis, and fatigue. No grade 4 toxicities, febrile neutropenia, or treatment-related deaths were observed. Pathological complete response (pCR; ypT0N0) was achieved in 8 (36.4%) patients, and 12 (54.5%) patients had pathologic down-staging compared with their clinical stage. aMVAC is a feasible regimen for geriatric patients with MIBC, achieving high treatment completion rates and acceptable toxicity. The simplified one-day protocol reduces hospital stay and logistical burden while maintaining therapeutic intensity. aMVAC represents a practical and feasible alternative in real-world, resource-limited settings. Clinical Trial Registration The trial was registered under clinical trial registry of India : CTRI/2021/10/037450.

  • Open Access

    Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting

    by Deepak Sundriyal, Sai Prasath, Harsha S. Prakash, Anusha Mruthyunjaya Swamy, Karthik Jayalingappa, Mayank Kapoor, Mahesh Koulagi, Deepa Joseph, Sweety Gupta, Parmod Kumar, et al.

    PURPOSE: Muscle-invasive bladder carcinoma (MIBC) poses major treatment challenges in low- and middle-income countries because of logistical and socioeconomic barriers limiting neoadjuvant chemotherapy (NAC) delivery. While dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) improves pathologic response and survival over gemcitabine-cisplatin, its multiday schedule reduces practicality. Accelerated MVAC (AMVAC), a single-day outpatient regimen, may offer a feasible alternative. This study evaluated the feasibility and safety of AMVAC in Indian patients with MIBC. METHODS: We conducted a single-arm feasibility study at the All India Institute of Medical Sciences, Rishikesh, India, between December 2021 and November 2024. Adults with stage II-III MIBC and cisplatin eligibility received 3-4 cycles of single-day AMVAC with pegfilgrastim support before radical cystectomy. Feasibility was defined as completion of ≥3 or 4 cycles within protocol-specified timeframes. Toxicities were graded using CTCAE v5.0, and outcomes were analyzed descriptively. RESULTS: Sixty patients were enrolled (mean age 55.2 ± 11.2 years; 90% male); 55 received neoadjuvant, and five adjuvant therapy. The mean number of chemotherapy cycles delivered was 3.87 ± 0.85. Feasibility outcomes were favorable, with 91.6% completing three and 76.6% completing four cycles within protocol timelines. Dose reductions for grade ≥3 toxicities were required in 13 patients (21.7%), whereas four patients discontinued treatment because of reduced creatinine clearance. Grade 3 adverse events occurred in 38.3%, most commonly anemia (16.7%), fatigue, and mucositis (13.3% each). Among neoadjuvant recipients undergoing cystectomy (n = 40), pathologic complete response (PCR) was achieved in 32.5% and pathologic downstaging was achieved in 55%. CONCLUSION: Single-day AMVAC is a feasible and tolerable NAC regimen in a resource-constrained setting, with encouraging PCR and manageable toxicity.